Polygenic risk scores improve identification of rare variant carriers in idiopathic pulmonary fibrosis patients.
This observational cohort study analyzed IPF patients from the Pulmonary Fibrosis Foundation Patient Registry (PFF-PR; n=888) and the UK PROFILE cohort (n=472 for validation). The study compared polygenic risk scores (PRS) for IPF—whole-genome PRS using C+T and SBayesRC methods, and a Sentinel-PRS from 19 known variants—against a clinical model based on patient history to identify carriers of rare qualifying variants (QVs) in genes linked to monogenic pulmonary fibrosis.
Main results showed inverse associations between all PRS types and QV carrier status. The whole-genome PRS using C+T had an odds ratio of 0.65 (95% CI 0.53-0.79), the SBayesRC method had an OR of 0.71 (95% CI 0.59-0.86), and the Sentinel-PRS had an OR of 0.77 (95% CI 0.63-0.94). Adding PRS to the clinical model improved discriminatory performance: the AUC increased from 0.62 to 0.68 for C+T (DeLong test p=9.54x10-4) and from 0.62 to 0.66 for SBayesRC (p=0.02).
Reclassification analysis showed correct reclassification of QV carriers in 22.8% with WG-PRSC+T, 20.8% with Sentinel-PRS, and 16.7% with WG-PRSSBayesRC. Safety data were not reported, as this was a registry-based cohort study. Key limitations include moderate overall discriminatory power and the observational design, which does not establish causation.
Practice relevance suggests that incorporating IPF-PRS into clinical models may enhance identification of rare variant carriers, potentially aiding decision-making for variant discovery. However, findings are associative and should not be overinterpreted.